Royal London Asset Management Ltd. Sells 94,267 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Royal London Asset Management Ltd. lowered its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 18.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 415,116 shares of the medical research company's stock after selling 94,267 shares during the quarter. Royal London Asset Management Ltd. owned 0.23% of IQVIA worth $98,370,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. First Foundation Advisors raised its holdings in shares of IQVIA by 3.8% in the 2nd quarter. First Foundation Advisors now owns 1,161 shares of the medical research company's stock worth $245,000 after buying an additional 43 shares in the last quarter. Invera Wealth Advisors LLC raised its holdings in shares of IQVIA by 0.3% in the 2nd quarter. Invera Wealth Advisors LLC now owns 14,506 shares of the medical research company's stock worth $3,183,000 after buying an additional 46 shares in the last quarter. Private Trust Co. NA raised its holdings in shares of IQVIA by 10.7% in the 3rd quarter. Private Trust Co. NA now owns 485 shares of the medical research company's stock worth $115,000 after buying an additional 47 shares in the last quarter. Oregon Public Employees Retirement Fund raised its holdings in shares of IQVIA by 0.3% in the 2nd quarter. Oregon Public Employees Retirement Fund now owns 15,668 shares of the medical research company's stock worth $3,313,000 after buying an additional 48 shares in the last quarter. Finally, Continuum Advisory LLC raised its holdings in shares of IQVIA by 3.3% in the 2nd quarter. Continuum Advisory LLC now owns 1,538 shares of the medical research company's stock worth $325,000 after buying an additional 49 shares in the last quarter. Institutional investors own 89.62% of the company's stock.

IQVIA Trading Down 1.9 %

Shares of NYSE:IQV traded down $3.90 during midday trading on Thursday, hitting $199.27. The company had a trading volume of 475,320 shares, compared to its average volume of 1,175,804. IQVIA Holdings Inc. has a 12 month low of $187.62 and a 12 month high of $261.73. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76. The stock has a market cap of $36.17 billion, a price-to-earnings ratio of 26.13, a PEG ratio of 2.06 and a beta of 1.49. The firm has a fifty day simple moving average of $216.54 and a 200 day simple moving average of $225.51.

Wall Street Analyst Weigh In

IQV has been the subject of a number of recent research reports. TD Cowen dropped their target price on IQVIA from $270.00 to $255.00 and set a "buy" rating for the company in a report on Friday, November 1st. Truist Financial dropped their price target on IQVIA from $286.00 to $265.00 and set a "buy" rating for the company in a report on Monday, November 4th. StockNews.com cut IQVIA from a "buy" rating to a "hold" rating in a report on Thursday, November 28th. Redburn Atlantic started coverage on IQVIA in a report on Monday, October 14th. They set a "buy" rating and a $276.00 price target for the company. Finally, Morgan Stanley dropped their price target on IQVIA from $280.00 to $265.00 and set an "overweight" rating for the company in a report on Monday, November 4th. Five research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $256.50.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.